Department of Surgery, Osaka Rosai Hospital, 1179-3, Nagasone-cho, Kita-ku, Sakai-city, , Osaka, 5918025, Japan.
Department of Surgery, Sakai City Medical Center, Sakai, Japan.
Gastric Cancer. 2022 Mar;25(2):422-429. doi: 10.1007/s10120-021-01251-z. Epub 2021 Sep 22.
Our previous report showed that surgical palliation maintained quality of life (QOL), improved solid food intake, and had an acceptable surgical safety among patients with malignant bowel obstruction (MBO) caused by advanced gastric cancer. This study performed a survival analysis stratified by the patients' QOL to elucidate its impact on survival.
Patients who underwent resection or bypass of the small intestine/colon or ileostomy/colostomy for bowel obstruction caused by peritoneal dissemination of gastric cancer were included. Validated instruments (EuroQoL-5 Dimensions) were used to assess QOL at baseline and 2 weeks, 1 month, and 3 months following surgical palliation. Postoperative improvement in oral intake was also evaluated using the Gastric Outlet Obstruction Scoring System (GOOSS). Univariate and multivariate survival analyses were performed using baseline characteristics and changes in QOL and GOOSS scores 2 weeks after surgery to determine prognostic factors.
We enrolled 60 patients with a median survival time of 6.64 (95% CI 4.76-10.28) months. Patients who received postoperative chemotherapy and had lower baseline C-reactive protein (CRP) levels, higher baseline albumin levels, better baseline EuroQoL-5 Dimensions (EQ-5D) scores, and improved oral intake after palliative surgery exhibited significantly better survival. Multivariate analysis identified postoperative chemotherapy, lower baseline CRP levels, and improved oral intake as independent prognostic factors.
The current study revealed that baseline QOL and postoperative QOL changes did not affect survival. Moreover, improved oral intake, lower baseline CRP levels, and postoperative chemotherapy were significant prognostic factors in patients who underwent palliative surgery for advanced gastric cancer with MBO.
我们之前的报告表明,手术姑息治疗维持了生活质量(QOL),改善了固体食物摄入,并在晚期胃癌引起的恶性肠梗阻(MBO)患者中具有可接受的手术安全性。本研究通过患者 QOL 分层进行生存分析,以阐明其对生存的影响。
纳入因胃癌腹膜扩散导致小肠/结肠切除或旁路、肠造口/结肠造口术治疗肠梗阻的患者。使用经过验证的工具(EuroQoL-5 Dimensions)在基线和手术姑息治疗后 2 周、1 个月和 3 个月评估 QOL。还使用胃出口梗阻评分系统(GOOSS)评估术后口服摄入的改善情况。使用基线特征以及术后 2 周 QOL 和 GOOSS 评分的变化进行单因素和多因素生存分析,以确定预后因素。
我们纳入了 60 例患者,中位生存时间为 6.64 个月(95%CI 4.76-10.28)。接受术后化疗且基线 C 反应蛋白(CRP)水平较低、基线白蛋白水平较高、基线 EuroQoL-5 Dimensions(EQ-5D)评分较好以及姑息性手术后口服摄入改善的患者的生存情况明显更好。多因素分析确定术后化疗、较低的基线 CRP 水平和改善的口服摄入是姑息性手术治疗晚期胃癌伴 MBO 患者的独立预后因素。
本研究表明,基线 QOL 和术后 QOL 变化不影响生存。此外,改善的口服摄入、较低的基线 CRP 水平和术后化疗是接受姑息性手术治疗晚期胃癌伴 MBO 患者的重要预后因素。